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Context: There is concern whether soy phytoestrogens may affect thyroid function. If true,
soy phytoestrogens may be expected to have a greater impact in subjects with subclinical
hypothyroidism.
Objective: The primary aimwas to determine the effect of soy phytoestrogen supplementation on
thyroid function, with a secondary aim of assessing the effects on cardiovascular risk indices in
patients with subclinical hypothyroidism.
Design and Setting:We conducted a randomized, double-blind, crossover study in a tertiary care
setting.
Participants: Sixty patients with subclinical hypothyroidism participated in the study.
Intervention: Patientswere randomly assigned to either low-dose phytoestrogen (30 g soy protein
with 2mgphytoestrogens, representative of aWestern diet) or high-dose phytoestrogen (30 g soy
proteinwith16mgphytoestrogens, representativeofa vegetariandiet) supplementation for8wk,
then crossed over after an 8-wk washout period.
Main Outcome Measures: The primary outcome was progression to overt hypothyroidism, with
secondary outcome measures of blood pressure, insulin resistance, lipids, and highly sensitive
C-reactive protein (hsCRP).
Results: Six female patients in the study progressed into overt hypothyroidismwith a standardized
rate ratio of 3.6 (95% confidence interval, 1.9, 6.2) after 16-mg phytoestrogen supplementation.
Both systolic and diastolic blood pressure decreased with 16 mg phytoestrogens, whereas systolic
pressure alone decreasedwith 2mg phytoestrogens. Insulin resistance (homeostasis model assess-
ment of insulin resistance, 3.5 0.09 vs. 2.6 0.08; P 0.02) and hsCRP (4.9 0.04 vs. 3.9 0.03;
P  0.01) decreased with 16 mg phytoestrogens. Lipid profile remained unchanged.
Conclusion: There is a 3-fold increased risk of developing overt hypothyroidism with dietary sup-
plementation of 16 mg soy phytoestrogens with subclinical hypothyroidism. However, 16-mg soy
phytoestrogen supplementation significantly reduces the insulin resistance, hsCRP, and blood
pressure in these patients. (J Clin Endocrinol Metab 96: 1442–1449, 2011)
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Soy foods have played an important role in the diets ofmany Asian countries for centuries, and in recent
years they have become increasingly popular inmanynon-
Asian countries as a result of their suggested health effects.
Postulated benefits of soy foods particularly due to their
phytoestrogen components include protection against
coronary heart disease (1, 2), breast and prostate cancer
(3–5), and osteoporosis (6), and alleviation of hot flushes
(7). Public interest in the health benefits of phytoestrogens
has led to the development of phytoestrogen supplements
and the fortification of foods with these soybean constit-
uents (8, 9).However, concernhasbeen expressed that soy
may adversely affect thyroid function in susceptible indi-
viduals (10, 11). In vitro studies have demonstrated that
phytoestrogens inhibit thyroid peroxidase (TPO), an en-
zyme involved in the synthesis of T3 and T4 (12, 13).
Subclinical hypothyroidism has a worldwide preva-
lence ranging from 1 to 10%; the highest age- and sex-
specific rates are in women older than 60 yr of age, ap-
proaching 20% in some reports (14, 15). Studies have
suggested that it is an independent risk factor for coronary
heart disease (16). Subclinical hypothyroidism during
pregnancy is also associated with adverse maternal and
neonatal outcomes (17–19). In this population group, the
potential impact of soy phytoestrogens on thyroid could
be of concern, although at the same time it could have
benefits in terms of improving cardiovascular risk.
Studies of phytoestrogen intakes in Western countries
indicate a typical average daily intake of around 2 mg
phytoestrogens (20, 21), whereas vegans consume an av-
erage of 16 mg (22). Phytoestrogens are found in high
quantities in soy products, but other dietary sources in-
clude vegetables, fruits, and nuts in lesser amounts. This
double-blind, crossover trialwas undertaken to determine
the effect of soy phytoestrogens on thyroid function and
cardiovascular disease risk markers in patients with sub-
clinical hypothyroidism. Soy protein was supplemented
with 16 mg phytoestrogens or 2 mg phytoestrogens as a
powder to be mixed with their daily dietary preparations.
Patients and Methods
Patients with subclinical hypothyroidism (TSH value between 5
and 15mU/liter; normal range, 0.5–4.7 mU/liter) with a normal
free T4 (fT4) were recruited after identification through routine
biochemical testing performed at Hull Royal Infirmary over a
12-monthperiod.The screening thyroid function testsweredone
4–8wkafter the initial biochemical testing.A total of 75patients
were initially identified, but 15 were excluded during screening:
10 patients could not tolerate the soy preparation due to its
unpalatability at taste testing before undertaking the study, and
in five patients thyroid function had returned to normal at
screening, suggesting transient thyroiditis. Exclusion criteria in-
cluded patients taking drugs that may interfere with thyroid
function; antihypertensive, insulin-sensitizing agents; lipid-low-
ering medications, as well as antibiotic use within the previous 6
months. Women who were contemplating pregnancy were ex-
cluded. At randomization and each subsequent visit, subjects
were instructed to maintain their level of physical activity
throughout the study. In addition, subjects were required to
avoid food products containing soy, alcohol, vitamin or mineral
supplementation, and over-the-counter medications. Dietary re-
inforcement was undertaken at each visit, together with mea-
surement of plasma phytoestrogen levels to ensure compliance.
A 24-h urine collection was made during the second phase to
measure urine iodine excretion.
Study design
A randomized, double-blind, crossover study was under-
taken. A total of 60 patients (age range, 44–70 yr) were ran-
domized for the study; 30 patients initiated with the 2 mg phy-
toestrogen with 30 g soy protein powder, and 30 patients on the
16 mg phytoestrogen with 30 g soy protein powder per day for
8 wk to be mixed with their daily dietary preparations (first
phase). After an 8-wk washout period, the participants received
the alternative supplementation for 8 wk (second phase).
An 8-wk time period was chosen for each arm because this
was the minimum time for phytoestrogen exposure that might
have been expected to affect thyroid function, given that the
half-life of T4 is around 7 d.
Each box of supplements that patients received contained the
number of sachets required for 8wk of supplementation plus six
sachets marked as reserve in case of trial material loss or any
delay in their final clinic attendance.
After completing the baseline tests, the subjects were ran-
domly assigned to either 16- or 2-mg phytoestrogen supplemen-
tation based on a computer-generated randomization list. Each
randomization number corresponded with one of the two pos-
sible interventions, and labeling of the identical boxes of study
preparation was done by personnel not involved in the trial.
Compliance was calculated by counting the returned sachets.
The primary outcome of the study was progression to overt
hypothyroidism, whereas secondary outcome measures were
blood pressure, homeostasis model assessment of insulin resis-
tance (HOMA-IR), lipids, andhighly sensitiveC-reactiveprotein
(hsCRP).Overt hypothyroidismwasdefined as a combinationof
TSH greater than 4.7 mU/liter and fT4 less than 9 pmol/liter.
Of the 60 patients randomized, six female patients withdrew
during the high-dose phytoestrogen supplementation due to pro-
gression to overt hypothyroidism, and another six female pa-
tients withdrew while on low-dose phytoestrogen supplementa-
tion [fourwith loose stools (ages 64, 52, 66, and 68 yr), onewith
use of antibiotics (age, 55 yr), and one lost to follow-up (age, 63
yr)]; however, the data from withdrawals were included as part
of intention-to-treat analysis.
Phytoestrogen composition
The low-dose phytoestrogen preparation consisted of 30 g of
soy protein concentrate (70% proteins) containing 2 mg of phy-
toestrogens, and the high-dose preparation contained 16 mg of
phytoestrogens. Analysis showed the composition of the dose
materials to be 54%genistein, 35%daidzein, and 12%glycitein
as aglycones and further confirmed that 90% of phytoestrogens
were in the primary glucoside form, with the remaining 10% as
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aglycones or acetyl andmalonyl glucosides. The soyprotein (Sol-
con F) and the phytoestrogens (Solgen 40) were supplied by Sol-
bar Industries Ltd. (Ashdod, Israel) and prepared by Essential
Nutrition, Ltd. (Brough, UK), who randomized the sachets.
Study measurements
At the beginning and end of each phase, after an overnight
fast, weight and blood pressure were measured, and blood sam-
ples were collected. Blood pressure was measured after the pa-
tients had been seated quietly for at least 5minwith the right arm
supported at heart level. Blood pressuremeasurementswere per-
formed using an automated device (NPB-3900; Nellcor Puritan
Bennett, Pleasanton, CA) during each study visit. Two readings
were obtained at the beginning of each visit at least 1 min apart.
If there was more than a 5-mm Hg difference in systolic blood
pressure between the two readings, a third readingwas obtained.
Fasting venous blood samples were collected and separated by
centrifugation at 2000  g for 15 min at 4 C, and the aliquots
were storedat80Cwithin1hof collection.Plasmaglucosewas
measured using a Synchron LX20 analyzer (Beckman Coulter,
Buckinghamshire, UK), and serum insulin was assayed using a
competitive chemiluminescent immunoassay performed using
the DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK).
The coefficient of variation of this method was 8%, calculated
using duplicate study samples. The analytical sensitivity was 2
U/ml. Insulin resistance was calculated using HOMA-IR (in-
sulin glucose)/22.5) (23). Total cholesterol, triglycerides, and
high-density lipoprotein cholesterol levels were measured enzy-
matically using a Synchron LX20 analyzer (Beckman Coulter).
Low-density lipoprotein cholesterol was calculated using the
Friedewald equation. All thyroid assays were performed on an
Abbott Architect i4000 immunoassay analyzer (Abbott Diag-
nostics Division, Berkshire, UK). The reference range for TSH
was 0.5–4.7 mU/liter, fT4 was 9–24 pmol/liter, and free T3 was
2.5–5.3 pmol/liter. Urinary iodine measurements in 24-h urine
collections were undertaken by inductively coupled plasma–
mass spectrometry to monitor for iodine repletion, and plasma
phytoestrogen measurement was undertaken by liquid chroma-
tography–tandem mass spectrometry (Central Science Labora-
tory, Sand Hutton, UK).
Statistical analysis
For a significant reduction in fT4, a sample size of 50 patients
in a crossover designwas calculated, giving 80%power to detect
a mean decrease of 0.4 nmol/liter of free T4, with a two-sided 
error of 0.05 (24).
Intention-to-treat analysis was performed. Wilcoxon’s signed-
rank test was used to compare thyroid function tests before and
after supplementationwith 2 and 16mg phytoestrogens, as well as
phytoestrogen data that violated the assumptions of normality
when tested using the Kolmogorov-Smirnov test. The period and
the carryover effect that may have occurred from the crossover
design were also tested using the appropriate Student’s t test.
Independent samples t test was used to compare plasma phy-
toestrogen levels after washout and after 2 mg/16 mg phytoes-
trogens. Statistical analysiswasperformedusingSPSS14.0 (SPSS
Inc., Chicago, IL). An arbitrary level of 5% statistical signifi-
cance (two-tailed) was assumed. The data are reported as
mean  SEM. All subjects gave their written informed consent,
and the protocol was approved by theHull and East Riding local
research ethics committee.
Results
The mean age of patients was 57.2  13.8 yr. There
were eightmales and 52 female subjects with subclinical
hypothyroidism. TPO antibodies, the marker for auto-
immune thyroid dysfunction, were positive (75 U/ml)
in 38 (63.3%) patients. Compliance was 98% in both
groups.
Six patients (10%) developed overt hypothyroidism after
high-dose phytoestrogen, and none after low-dose phytoes-
trogensupplementation.Ofthesesixpatientswhodeveloped
overt hypothyroidism, three had high-dose phytoestrogen
supplementation before low-dose phytoestrogen, and three
had high-dose phytoestrogen supplementation after low-
dose phytoestrogen supplementation (Fig. 1). All of the sub-
jects whowithdrew from the study came back to clinic for
an end-of-study visit where all of the outcomes were mea-
sured. All six subjects were diagnosed as having overt hy-
pothyroidism during their end-of-study visit after the
8-wk high-dose phytoestrogen supplementation period,
when theywere found to have raised TSHofmore than 10
mU/liter and a low fT4 of less than 9 pmol/liter, i.e. overt
hypothyroidism.
The six patients who developed overt hypothyroidism
started on levothyroxine on the basis of their biochemical
testing alone and continued to receive levothyroxine sup-
plementation after 6 months.
All six patients who developed overt hypothyroidism
were females, i.e.11.5%of females in this studydeveloped
overthypothyroidism.All sixpatientswhowithdrewfrom
study were females, reflecting that 13% of females who
completed the study developed overt hypothyroidism.
Only one patient who developed overt hypothyroidism
during the study had TPO antibody positivity.
Although six patients receiving 16-mg phytoestrogen
supplementation advanced from subclinical to overt hy-
pothyroidism and no patients advanced while receiving
2-mgphytoestrogen supplementation, themeanTSH, fT4,
and free T3 levels were not statistically different between
the two groups. Therewere also no statistically significant
changes in any of these parameters when the two groups
(i.e. the groupwhohad 2mgphytoestrogen first, followed
by the 16-mg phytoestrogen supplementation, and the
group who had 16mg phytoestrogen first followed by the
2-mg phytoestrogen supplementation) were analyzed sep-
arately. There were no period effects or carryover effects
in any of the parameters. Thyroid antibody positivity did
not alter before or after either supplement. This suggests
that neither baseline thyroid function tests nor thyroid
antibody positivity predicts progression of patients with
subclinical hypothyroidism to overt hypothyroidismwith
high-dose phytoestrogen supplementation.
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For the six patients who developed overt hypothyroid-
ism after high-dose phytoestrogen supplementation, TSH
values increased by 57% (8.0  0.8 vs. 13.1  0.7 mU/
liter; P  0.05), and fT4 values decreased by 25% (12 
0.4 vs. 8.8 0.1 pmol/liter; P 0.05). In these
six patients, TSH values ranged from 12–14
mU/liter, and fT4 values ranged from 8.6–8.9
pmol/liter.When the six patientswho developed
overt hypothyroidism were compared with the
rest of the patients, there were no significant dif-
ferences in post high-dose phytoestrogen supple-
mentation daidzein levels (26.3 1 vs. 25 0.9
ng/ml;P0.5) or genistein levels (46.10.9 vs.
48.6  1.2 ng/ml; P  0.1). The urine iodine
levels did not differ between patients who
developed overt hypothyroidism compared
with the remainder of the subjects (median
interquartile range, 272.5  10.2 vs. 234 
6.2 g/d; P  0.2).
There was a significant reduction in systolic
blood pressure and diastolic blood pressure af-
ter 16-mg phytoestrogen supplementation.
There was also a significant reduction in sys-
tolic, but not in diastolic, blood pressure after
the 2-mg phytoestrogen supplementation.
There were no significant changes in weight
after either the 16- or 2-mg phytoestrogen sup-
plementation (Table 1).
There was a significant improvement in in-
sulin resistance measured using HOMA-IR af-
ter the 16-mg phytoestrogen supplementation
but not after the 2-mg phytoestrogen supple-
mentation (Table 1). There was a significant
improvement in hsCRP, amarker for inflammation in ath-
erosclerosis, after 16mg phytoestrogen but not after 2-mg
phytoestrogen supplementation. There were no signifi-
75 patients screened 
10 patients – could not tolerate preparation 
5 patients – thyroid function normalised 
               60 Randomised 
Soy protein 30g/day + 
Isoflavones 16mg/day x 
8 weeks. 
(n= 30) 
(Withdrawals = 3 due to 
hypothyroidism) 
Soy protein 30g/day + 
Isoflavones 2 mg/day 
x 8 weeks. 
(n=30) 
(Withdrawals = 6) 
 
Soy protein 30g/day + 
Isoflavones 2 mg/day 
x 8 weeks 
(n=27) 
(Withdrawals = 0) 
 
Soy protein 30g/day + 
Isoflavones 16mg/day x 
8 weeks 
(n=24) 
(Withdrawals = 3 due to 
hypothyroidism) 
Washout & 
Cross over (8 weeks) 
Total number of patients who completed both phases = 48  
FIG. 1. Flow chart describing the progress of patients through the trial.
TABLE 1. Subject characteristics and effects on cardiovascular risk at the start of the trial and 3 months after
supplementation
2 mg phytoestrogen/
30 g soy protein/d
16 mg phytoestrogen/
30 g soy protein/d
P (between-
supplementation
difference)Baseline 3 months P value Baseline 3 months P value
Weight (kg) 78.4  2.1 78.2  1.8 0.4 79.1  2.3 78.9  1.9 0.4 0.8
BMI (kg/m2) 29.2  0.6 29.1  0.8 0.4 29.6  0.7 29.4  0.4 0.4 0.8
SBP (mm Hg) 141.4  2.0 136.8  1.8 0.03 140.7  2.4 133.6  2.8 0.01 0.01
DBP (mm Hg) 75.8  1.0 74.9  1.4 0.4 76.7  1.8 72.1  1.4 0.02 0.01
Plasma glucose
(mmol/liter)
5.3  0.03 5.2  0.04 0.2 5.4  0.2 4.9  0.05 0.01 0.01
Insulin (IU/ml) 27.5  1.2 26.9  0.9 0.1 27.3  0.9 20.8  1.2 0.01 0.01
HOMA-IR 3.5  0.08 3.4  0.06 0.4 3.5  0.09 2.6  0.08 0.01 0.01
TC (mmol/liter) 5.5  1.1 5.2  0.9 0.7 5.4  0.8 5.0  0.2 0.3 0.8
LDL (mmol/liter) 3.5  0.2 3.3  0.1 0.2 3.4  0.1 3.2  0.2 0.2 0.8
HDL (mmol/liter) 1.3  0.02 1.4  0.09 0.3 1.2  0.05 1.4  0.03 0.1 0.3
TG (mmol/liter) 1.8  0.05 1.6  0.03 0.1 1.9  0.02 1.6  0.04 0.3 0.2
CRP (mg/liter) 4.8  0.08 4.6  0.06 0.1 4.9  0.04 3.9  0.03 0.02 0.01
BMI, Body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; LDL, low-density
lipoproteins; HDL, high-density lipoproteins; CRP, C-reactive protein. To convert values for glucose to milligrams per deciliter, divide by 0.056. To
convert values for insulin to picomoles per liter, multiply by 6. To convert values for cholesterol to milligrams per deciliter, divide by 0.0259. To
convert values for triglycerides to milligrams per deciliter, divide by 0.0113.
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cant changes in lipid profile after either the 16- or 2-mg
phytoestrogen supplementation (Table 1).
Thebaselineplasmaphytoestrogenvalueswereconsistent
with the standard United Kingdom diet (21). The levels of
phytoestrogens after thewashout phasewere comparable to
the baseline levels (daidzein, 2.1 0.3 vs. 2.2 0.1 ng/ml,
P 0.8; and genistein, 2.6 0.7 vs. 2.5 0.2 ng/ml), con-
firming compliance of patients with the study protocol and
avoidance of extra dietary sources of phytoestrogens.
There was a significant increase in plasma phytoestrogens
after 16-mg supplementation compared with 2-mg phy-
toestrogen supplementation (Table 2). The plasma levels
of non-soy phytoestrogens such as formononetin, biocha-
ninA, and coumestrolwere lowand static before and after
2- and 16-mg phytoestrogen supplementations. The 24-h
urine iodine estimation showed adequate dietary iodine
repletionwith a urinary iodine excretion of 262 18g/d
(median  interquartile range).
Discussion
This study showed that soy phytoestrogen supplementa-
tion at a level found in a vegetarian diet (16 mg) appeared
to have a detrimental effect on thyroid status in patients
with subclinical hypothyroidism,whereas phytoestrogens
at a level equivalent to that seen in a normal Western diet
(2 mg) did not. Although some studies have found no
differences in thyroid function in vegans compared with
omnivores (25, 26), these data are in accord with a report
showing that the geometric mean TSH concentration, ad-
justed for age and body mass index, was 29% higher in
vegans than in omnivores in the United Kingdom (27).
This is supported by animal studies showing synergism of
soy phytoestrogens with iodine deficiency causing hypo-
thyroid effects in rats (28). Indeed, in vitro studies have
demonstrated that the phytoestrogen inhibits TPO, an en-
zyme involved in the synthesis of T3 and T4 (12, 13). The
subjects in the present studywere iodine replete, as seen by
the urinary iodine concentration of greater than 100 g/
liter (29). The minimum daily requirement for iodine is
150g/d,which corresponds in general to aurinary iodine
concentration of 100–150 g/d.
Of the 60 patients recruited, six of the 52 female sub-
jects (11.5%) progressed into overt hypothyroidism after
the16-mgphytoestrogenarmof the6-monthperiod in this
study. This suggests that the risk of developing overt hy-
pothyroidism is much higher in females who have sub-
clinical hypothyroidismwith high-dose phytoestrogen in-
take. However, because only 11.5% of the study subjects
were male, it was not possible to determine the risk of
development of overt hypothyroidism in males. The overt
hypothyroidism that developed appeared permanent,
with no reversal on phytoestrogen withdrawal, but the
underlyingmechanism isunclear, althoughaccelerationof
the underlying autoimmune process cannot be excluded.
In aprospective study looking into the spontaneous course
of hypothyroidism in females, the rate of progression of
subclinical hypothyroidism to overt hypothyroidism was
5.6%/yr (30). Extrapolating the data from this 8-wk study
to give a rate of progression per year, it was expected that
in our study population, 3.36 cases per year would prog-
ress to overt hypothyroidism; this translates into a stan-
dardized rate ratio of 3.6 (95% confidence interval 1.9,
6.2), i.e. supplementation with 16 mg phytoestrogen
caused a 3-fold increase in progression from subclinical to
overt hypothyroidism in this study. This incidence in our
study is higher than the 4.3%/yr risk for progression from
subclinical to overt hypothyroidism found in TPO anti-
body-positive women and the 2.6%/yr risk for subclinical
hypothyroid TPO antibody-negative women in the
Whickham survey (31). Although TPO antibody positiv-
ity is a known risk factor for the progression to overt
hypothyroidism and 63%of study participants were TPO
antibody positive, only one patient who developed overt
hypothyroidism in the present study was TPO antibody
positive. This suggests that a relatively higher proportion
of patients in this study had TPO-negative autoimmune
subclinical hypothyroidism. None of the subjects had
prior thyroid surgery or radioiodine therapy. The 24-h
TABLE 2. Plasma isoflavone levels and thyroid functions at the start of the trial and 3 months after supplementation
2 mg phytoestrogen/
30 g soy protein/d
16 mg phytoestrogen/
30 g soy protein/d
P (between-
supplementation
difference)Baseline 3 months P value Baseline 3 months P value
fT3 (pmol/liter) 4.0  0.06 4.4  0.09 0.2 4.2  0.8 4.3  0.6 0.4 0.6
fT4 (pmol/liter) 11.8  0.1 11.9  0.4 0.1 12.2  0.1 11.3  0.9 0.1 0.4
TSH (mU/liter) 7.8  0.4 7.5  0.1 0.4 7.9  0.3 8.4  0.8 0.3 0.7
Daidzein (ng/ml) 2.1  0.3 11.6  0.2 0.01 2.2  0.1 26.2  0.1 0.01 0.01
Genistein (ng/ml) 2.6  0.7 10.9  0.3 0.01 2.4  0.2 46.5  0.6 0.01 0.01
fT3, Free T3.
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urine iodine estimation showed adequate dietary iodine
repletion,which excludes iodinedeficiencyas the cause for
the hypothyroidism seen in this group.
There are currently no data to guide what effect longer
periods of exposure would have on thyroid function, with
the possibilities that more overt hypothyroidism may re-
sult, stabilization may occur, or thyroid function could
improve with thyroid adaptation to the phytoestrogen
load. Gastrointestinal side effects are recognized adverse
effects of soy protein and/or phytoestrogens (32); how-
ever, it appears that all the patients who developed gas-
trointestinal side effects severe enough to withdraw from
the study did so during the low-dose phytoestrogen sup-
plementation phase.
A beneficial effect on the cardiovascular risk indices
was observed, with a significant reduction of blood pres-
sure, hsCRP, and insulin resistance after the higher 16-mg
phytoestrogen supplementation in this study. Epidemio-
logical observations of diet and cardiovascular disease in
Japan and China have linked soy-product consumption
with a reduced cardiovascular risk (33, 34). Studies of
phytoestrogen intakes in Western countries indicate an
average daily intake of approximately 2 mg phytoestro-
gens (20, 21), equivalent to the low-dose phytoestrogen
preparation used here. Vegetarians have higher phytoes-
trogen intake (22), with levels corresponding to the 16-mg
phytoestrogen supplementation of this study.
Therewas a statistically significant reduction in systolic
blood pressure of 7.2  2.6 mm Hg and diastolic blood
pressure of 4.3  1.2 mm Hg after 16-mg phytoestrogen
supplementation in this study. The magnitude of the re-
duction in blood pressure was as great as that seen in
therapeutic trials on hypertension that have shown a
marked reduction in cardiovascular risk (35–37), support-
ing the potential value of such a dietary supplementation.
An improvement in systolic pressure alone was seen
with 2 mg phytoestrogens in this study. This would sug-
gest that there is a dose-response effect, with the 16-mg
phytoestrogen supplementation being more effective. It
has been suggested that an antihypertensive effect may be
mediated via the action of phytoestrogens on endothelial
cell function (38). However, in a study in type 2 diabetes
patients treated with 132-mg tablets of phytoestrogens
alone without soy protein, there was no antihypertensive
effect and there was no effect on cardiovascular disease
markers (39). This suggests that a synergistic matrix
effect between the soy proteins with the phytoestrogens
may be responsible for any cardiovascular disease
changes because both supplements contain the same
amount of protein. The blood pressure-lowering effects
of soy phytoestrogens reported in the literature are con-
flicting (40–42); however, the studies are difficult to com-
pare because different soy phytoestrogen/placebo/com-
parator preparations have been used in a diverse range of
study populations.
There was a significant improvement in insulin resis-
tance after the 16-mg phytoestrogen supplementation.
This is in accord with studies that show soy phytoestro-
gens improving insulin resistance in postmenopausal
women and those with type 2 diabetes (24, 43). Primate
studies have suggested that consumption of isoflavone-
containing soy protein dose-dependently increased insulin
responses to the glucose challenge and decreased plasma
adiponectin, whereas isoflavone-depleted soy protein de-
creased body weight and had no effect on plasma adi-
ponectin concentrations (44). In addition, studies have
shown that phytoestrogen alone without soy protein was
ineffective in reducing insulin resistance, suggesting a po-
tential matrix effect (42, 45).
There was also a significant improvement of hsCRP
after 16 mg phytoestrogen but not after the 2-mg phy-
toestrogen phase, suggesting that higher phytoestrogen
doses may have an antiinflammatory effect in this study.
It is now established that hsCRP is an important cardio-
vascular riskmarker (46). In another study, phytoestrogen
supplementation alone did not have any effects on hsCRP
(47); however, soy protein along with phytoestrogen im-
proved hsCRP in patients having type 2 diabetes with ne-
phropathy (48), again suggesting a potentialmatrix effect.
Therewas no significant change in the lipid profilewith
either high- or low-dose phytoestrogen supplementation
in this study. In other studies, higher doses of phytoestro-
gens (66–166mg/d) alongwith soy protein or isolated soy
protein are reported to improve the lipid profile (40, 43,
49), but not seen with isolated phytoestrogen supplemen-
tation (50, 51). This also supports a potentialmatrix effect
between the protein and the phytoestrogens.
This study suggests that a number of cardiovascular
risk factors improved with high-dose phytoestrogens and
a number with low-dose phytoestrogens. However, these
risk factors may get worse with the progression of sub-
clinical to overt hypothyroidism if left undiagnosed or not
treated over time. A beneficial effect of the phytoestrogens
on these risk factors over the initial short period of treat-
ment may result, but with deleterious effects resulting
from the induction of overt hypothyroidism.
Because all the patients were Caucasians, it will be dif-
ficult to generalize to other population groups. The ma-
jority of patients in this studywere females, but subclinical
hypothyroidism is more common in females. Six patients
withdrew while they were on low-dose phytoestrogens;
however, the dropout rate was better than other studies
involving nutritional supplementation. The safety and ef-
ficacy of higher doses of phytoestrogens, such as those
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found innutritional supplements, and thepotentialmatrix
effect were not ascertained in this study and need future
evaluation. This study is a comparative study of two dif-
ferent doses of phytoestrogenswithin the same soyprotein
matrix, but it lacks a true placebo arm with a supplemen-
tation of soy protein alone that is isoflavone free or an
alternative protein such as casein to replace the soy pro-
tein. However, the two doses of phytoestrogens studied
reflect the typical Western and vegetarian diets.
In conclusion, soy phytoestrogen supplementation at a
level reflecting that found in a vegetarian diet appeared to
precipitate overt hypothyroidism, especially in female pa-
tients with subclinical hypothyroidism. This suggests that
female vegetarian patients with subclinical hypothyroid-
ism may need more careful monitoring. Conversely, phy-
toestrogen supplementation showed a beneficial dose-de-
pendent effect on the cardiovascular risk profiles in this
patient population.
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